SARASOTA, FL - Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that CEO Kelvin Cooper, Ph.D., will participate in three upcoming industry conferences.
Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1
Dr. Cooper is scheduled to attend the Maxim Growth Summit on October 14, 2026, in New York City. He will also attend and present at the ThinkEquity Conference on October 15, 2026, in New York City. Later in the month, Dr. Cooper will present a poster on Nu-3 preclinical data at IDWeek on October 22, 2026, in Washington D.C.
Details are as follows:
|
Event: |
Maxim Growth Summit |
|
|
Date: |
October 13-14, 2026 |
|
|
Location: |
Hard Rock Hotel, New York City |
|
Event: |
ThinkEquity Conference |
|
|
Date: |
October 15, 2026 |
|
|
Location: |
The Mandarin Oriental Hotel, New York City |
|
|
Presentation: |
Nu-3 – A Novel, Broad Spectrum Antimicrobial Compound with High In- Vitro |
|
|
Presentation Time: |
3:30 pm |
|
Event: |
IDWeek |
|
|
Date: |
October 21-24, 2026 |
|
|
Location: |
Walter E. Washington Convention Center, Washington, D.C. |
The conferences provide opportunities for Lakewood-Amedex to engage with members of the investment, biotechnology, and infectious disease communities and highlight the Company's ongoing development programs Bisphosphocin® antimicrobial technology.
About Lakewood-Amedex Biotherapeutics, Inc.
Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Contacts:
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
Michelle Katsel
(201) 790-3390
mkatsel@tiberend.com
Additional Contact
David Shapiro
B2i Digital, Inc.
+1 212-579-4844
david@b2idigital.com
B2i Digital Social Media
LinkedIn
X
Facebook
Instagram
YouTube
TikTok
Stocktwits
Reddit
Pinterest
Threads
